Protagonist Therapeutics (PTGX) Long-Term Deferred Tax (2018 - 2020)

Protagonist Therapeutics (PTGX) has 3 years of Long-Term Deferred Tax data on file, last reported at $1.1 million in Q1 2020.

• For the quarter ending Q1 2020, Long-Term Deferred Tax rose 126.36% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2020 stood at $1.1 million (up 126.36% YoY), and the FY2019 full-year result was $1.4 million, up 117.78% from the prior year.
• Long-Term Deferred Tax retreated to $1.1 million in Q1 2020, from $1.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $2.1 million in Q3 2019 to a low of $478000.0 in Q1 2019.
• A 3-year average of $1.3 million and a median of $1.3 million in 2019 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax soared 117.78% in 2019 and jumped 126.36% in 2020, its largest moves.
• Tracing PTGX's Long-Term Deferred Tax over 3 years: stood at $658000.0 in 2018, then soared by 117.78% to $1.4 million in 2019, then retreated by 24.49% to $1.1 million in 2020.
• Business Quant data shows PTGX's Long-Term Deferred Tax at $1.1 million in Q1 2020, $1.4 million in Q4 2019, and $2.1 million in Q3 2019.